WHITE PAPER

caidya®

Navigating Major Inflection Points from IND to Approval:

A Strategic White Paper on Indication Clarity, Regulatory Alignment, and Quality-by-Design in Oncology Development

Adam Callahan, MS, MBA
VP Global Therapeutic Area Head, Oncology & Hematology

March, 2026

Executive Summary

The journey from Investigational New Drug (IND) submission to regulatory approval represents one of the most complex, capital-intensive, and strategically sensitive undertakings in the life sciences industry. In oncology—where science is advancing rapidly, regulatory pathways are evolving, and patient populations are increasingly molecularly defined—success requires far more than scientific innovation alone. It demands deliberate planning across major development inflection points, rigorous incremental evidence generation, early and continuous regulatory engagement, and the disciplined application of Quality-by-Design (QbD) principles.

This white paper expands upon key insights shared during the OCT West Coast 2026 session and accompanying discussion, providing a structured, narrative-driven framework for navigating critical transition points from Pre-IND through approval. It integrates regulatory trends, translational strategy, CMC scalability, and precision oncology considerations into a cohesive model designed to reduce risk, prevent clinical holds, and strengthen approval probability.



Figure 1. Overview of the IND to Approval Journey

1

Understanding Major Inflection Points in Drug Development

Drug development is not a linear process; rather, it is characterized by predictable but high-risk transition points that require strategic foresight. These inflection points include the Pre-IND meeting, IND submission, first-in-human (FIH) dose escalation, transition from Phase I to Phase II, End-of-Phase II regulatory alignment, pivotal Phase III trials, and post-marketing commitments.

For oncology programs in particular, these transitions can span 10 to 12 years or longer. Each stage requires incremental evidence generation—building a cumulative body of safety, efficacy, pharmacology, and manufacturing data that aligns with the evolving Target Product Profile (TPP). Failure to anticipate regulatory expectations at any of these junctures often results in timeline delays, resource inefficiencies, or clinical holds.



Figure 2. Major Inflection Points Across the Drug Development Lifecycle

Regulatory Trend: In 2024 alone, FDA and EMA approved 28 new or expanded oncology indications and 10 new oncology agents in Q4, covering approximately 34 solid tumor types and 10 hematologic malignancies. More than two-thirds of these approvals were biologics or biosimilars.

2

The Evolving Oncology Regulatory Environment

The oncology regulatory landscape is increasingly characterized by accelerated pathways designed to address unmet medical need while preserving patient safety. Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review mechanisms are now central components of oncology strategy.

Recent data indicate that over 65% of oncology approvals in 2024 leveraged one of these expedited pathways. Regulators are also adapting to rapidly evolving modalities—including CAR-T therapies, antibody-drug conjugates (ADCs), multi-specific antibodies, and gene therapies—reflecting a 12% increase in trial activity since 2019. Novel oncology mechanisms now account for nearly 25% of new trial starts.

Regulatory focus has expanded to include biomarker-driven development, real-world evidence (RWE), adaptive trial designs, and increased sponsor interaction. The era of precision medicine demands early indication clarity, measurable endpoints, and patient-specific targeting strategies.

Key Trends

- Greater focus on treating solid tumors through molecularly stratified, combination regimens
- Liquid biopsies/Companion Diagnostics (CDx)/Next-Gen Sequencing (NGS) for early detection, optimized therapeutic decisions, and non-invasive monitoring of tumor/patient
- Rise of radiopharmaceuticals
- AI-driven drug discovery
- A 12% increase in trial activity since 2019 focusing on novel modalities like ADCs, CAR-T (cell therapy), and multi-specific antibodies
- These novel oncology mechanisms account for nearly 25% of trial starts

Figure 3. Growth of Novel Oncology Modalities and Trial Activity

3

The Strategic Importance of the Pre-IND Meeting

The Pre-IND meeting—formally a Type B meeting under 21 CFR 312.82—serves as a foundational alignment opportunity between sponsor and regulator. Typically held approximately one year prior to IND submission, it aims to prevent clinical holds and optimize development plans.

Effective Pre-IND preparation requires disciplined focus. Sponsors should limit questions to 5–7 targeted areas of ambiguity and present a briefing package of approximately 30–50 pages. This package must clearly articulate proposed clinical design, CMC strategy, nonclinical adequacy, biomarker integration, and translational roadmap.

Critically, the Pre-IND meeting is not merely procedural. It is strategic. Sponsors that arrive with clearly defined patient populations, measurable endpoints, and contingency planning demonstrate development maturity—building regulatory confidence early in the lifecycle.

The Briefing Package:

- Maximize effectiveness by preparing a comprehensive briefing package that includes:
  - Proposed clinical trial design
  - CMC strategy
  - Key nonclinical data
- Your opportunity to present your drug development program to the FDA before the actual meeting.
- It should be thorough yet concise, typically around 30-50 pages.

Key components:

- Executive summary outlining your drug's mechanism of action, target indication, and development plan
- Preliminary efficacy data from animal models or in vitro studies
- Summary of key toxicology findings and proposed safety monitoring plan
- Overview of your CMC strategy, including any novel formulation approaches
- Proposed clinical trial design, including patient population, dosing rationale, and endpoints.

Figure 4. Key Components of an Effective Pre-IND Briefing Package

Figure 5. Key Cross-functional team for a Pre-IND Briefing

4

Translational Strategy: Bridging Bench to Bedside

The transition from nonclinical studies to human trials is frequently referred to as the 'valley of death' in drug development. A robust translational strategy mitigates this risk by aligning mechanism-of-action data, toxicology findings, pharmacokinetics, and biomarker hypotheses with clinical endpoints.

Early biomarker integration enhances patient selection and trial efficiency. Adaptive trial designs allow rapid signal detection and informed decision-making. In oncology, precision medicine principles require that sponsors define molecularly specific populations early—recognizing that a cancer is no longer defined solely by tissue origin but by genomic and immunologic context.



Figure 6. Translational Strategy Framework from Discovery to Clinical Development. Reference: Journal for ImmunoTherapy of Cancer 2022

5

Optimizing CMC Strategy and Embedding Quality-by-Design

Chemistry, Manufacturing, and Controls (CMC) strategy must balance flexibility with scalability. In early development, particularly first-in-human trials, over-engineering the CMC package can delay progress and inflate costs. Instead, a phase-appropriate control strategy focused on critical quality attributes (CQAs) is recommended.

Sponsors must plan for scalability from Phase I through commercialization, incorporating modular manufacturing approaches and early stability-indicating methods. Stability data are essential components of the IND submission, assuring regulators that product integrity will be maintained throughout its intended shelf life.

Embedding Quality-by-Design (QbD) principles from program inception strengthens inspection readiness, protects data integrity, and improves cross-functional consistency across the development lifecycle.

Conclusion: A Cohesive, Proactive Development Model

Successful navigation of the IND-to-approval journey requires integration—scientific rigor, regulatory foresight, translational clarity, scalable manufacturing, and embedded quality systems working in concert. Innovation alone is insufficient. Strategic discipline across each inflection point ultimately determines whether promising science reaches patients.

By defining indication clarity early, aligning regulatory strategy proactively, incorporating biomarker-driven precision, and embedding Quality-by-Design principles throughout development, sponsors can meaningfully improve approval probability and accelerate access to life-changing oncology therapies.

caidya®

caidya®

Adapting at the Speed of Science

Caidya is a global, full-service CRO that brings expertise, agility to navigate complex trials, and global access to patients, that yields the high-quality data you need to make informed decisions.

caidya.com